Primary ovarian insufficiency

Primary ovarian insufficiency is an endocrine condition characterised by loss or marked reduction of ovarian follicular function before the age of 40, resulting in impaired estradiol secretion, altered ovulation and a compensatory increase in gonadotropins, particularly FSH. Clinically, it does not necessarily correspond to a complete and irreversible cessation of ovarian activity, but describes a dynamic spectrum in which function may be fluctuating, intermittent or residual, despite a biochemical profile consistent with hypergonadotropic hypogonadism.

The clinical impact of primary ovarian insufficiency is not limited to fertility. The premature reduction in oestrogen exposure interferes with bone homeostasis, cardiovascular health, sexual function, neuropsychological wellbeing and quality of life. For this reason, the condition should be regarded not only as a gynaecological and reproductive disorder, but as a systemic endocrine syndrome requiring aetiological assessment, replacement therapy and long-term monitoring.

The epidemiology of primary ovarian insufficiency is complex because it depends on the definition used, the age of the population studied, the presence or absence of iatrogenic causes and the sensitivity of diagnostic pathways. In clinical practice, the condition affects a substantial proportion of women of reproductive age and is increasingly recognised as greater attention is paid to amenorrhea, infertility and symptoms of hypoestrogenism in younger women. The most recent pooled estimates indicate a global prevalence of approximately 3.5%, although this figure includes highly heterogeneous subgroups and should be interpreted as a broad epidemiological estimate rather than a uniform value applicable to every setting.

The age distribution is not random. Primary ovarian insufficiency may present as early as adolescence with delayed puberty or primary amenorrhea in the most severe forms of gonadal dysgenesis or impaired formation of the follicular pool, although it is more frequently identified in young adulthood through oligomenorrhea, secondary amenorrhea, infertility or symptoms of oestrogen deficiency. This heterogeneity of onset reflects the diversity of pathogenic mechanisms. Some patients are born with a quantitatively reduced follicular reserve, others undergo accelerated depletion, while others retain residual follicles for a period of time but experience ineffective or intermittent maturation.

The main risk factors include genetic causes, which represent one of the most relevant categories, particularly in non-iatrogenic forms. X chromosome abnormalities, including Turner syndrome and mosaicism, have a well-documented role, as does the FMR1 premutation and a growing number of variants in genes involved in meiosis, DNA repair, maintenance of the follicular pool and steroidogenesis. A family history of early menopause, unexplained amenorrhea or ovarian insufficiency in first-degree relatives is therefore highly relevant, as it suggests an intrinsic biological vulnerability of the ovary.

A second group of risk factors includes iatrogenic causes. Chemotherapy, pelvic radiotherapy or total body irradiation, repeated or extensive ovarian surgery, treatment of haematological and oncological diseases and certain post-transplant conditions may permanently or partially reversibly damage the follicular reserve. The risk depends not only on the type of treatment, but also on age at exposure, cumulative dose, radiation field and pre-existing ovarian reserve. The therapeutic history must therefore always be reconstructed accurately, even when the causative exposure occurred many years earlier.

The autoimmune category is epidemiologically relevant but more difficult to quantify because no single serum biomarker can reliably identify all immune-mediated forms. The association with other autoimmune endocrinopathies, particularly autoimmune adrenal insufficiency and autoimmune thyroiditis, nevertheless requires a high index of suspicion in patients with polyautoimmunity or a suggestive personal and family history. At the same time, environmental factors such as cigarette smoking, gynaecological surgery and possible toxic exposures may contribute to earlier follicular depletion in predisposed individuals, although the evidence is less consistent than for genetic and iatrogenic forms.

Finally, the epidemiological relevance of primary ovarian insufficiency is increased by the burden of its long-term consequences. A woman who develops hypoestrogenism at a young age accumulates more years of exposure to skeletal, cardiovascular, sexual and neuropsychological risks than a woman who reaches menopause at the expected age. This explains why the clinical epidemiology of the condition cannot be interpreted solely in terms of amenorrhea and infertility, but should instead be regarded as the epidemiology of a chronic endocrine syndrome with multisystem consequences.

Primary ovarian insufficiency is the final outcome of different aetiopathogenic mechanisms that converge in a reduction of follicular function before the age of 40. Under physiological conditions, ovarian function depends on the integrity of the follicular reserve, normal follicular maturation and appropriate communication between the hypothalamic-pituitary-ovarian axis and the granulosa and theca cell compartments. When the number of follicles becomes critically reduced, or when the remaining follicles can no longer mature or respond effectively to gonadotropin stimulation, production of estradiol and inhibin decreases, hypothalamic-pituitary negative feedback is reduced and levels of FSH, and often LH, rise.

From an aetiological perspective, the classic forms arise from four major categories. The first comprises genetic and chromosomal causes, in which the defect affects gonadal formation, maintenance of the oocyte pool, meiosis, DNA repair or follicular survival. The second includes autoimmune mechanisms, in which ovarian damage may occur within the broader context of endocrine autoimmunity. The third consists of iatrogenic forms, in which follicular damage follows exposure to gonadotoxic drugs, radiation or surgery. The fourth includes idiopathic cases, which remain numerous but probably encompass many genetically or biologically determined conditions that have not yet been fully elucidated.

In genetic forms, the pathogenic mechanism varies according to the defect involved. X chromosome abnormalities interfere with the normal development and maintenance of ovarian tissue because a substantial proportion of the genes required for folliculogenesis and oocyte survival are located on the X chromosome. The FMR1 premutation is associated with increased vulnerability of the follicular reserve, while variants in genes involved in repairing DNA breaks, meiotic recombination or genomic stability cause accelerated oocyte loss through apoptosis or maturational arrest. The biological result is an ovarian reserve that is quantitatively insufficient or qualitatively ineffective from a very early age.

In autoimmune forms, the ovary may be affected by direct immune-mediated inflammation or by damage occurring within autoimmune polyglandular syndromes. The target cannot always be identified precisely and serological confirmation is difficult, which is why an autoimmune diagnosis is often inferential and based on the clinical context, the presence of adrenal autoantibodies and the association with other autoimmune diseases. When damage involves the steroidogenic or follicular compartment, the consequence is a progressive loss of oestrogen production and ovulatory capacity, with a clinical pattern that may initially be intermittent and become more stable over time.

< b>Iatrogenic forms clearly illustrate the pathophysiology of follicular depletion. Chemotherapeutic agents, particularly those with a high alkylating potential, and radiation cause DNA damage, oocyte apoptosis and destruction of the follicular microenvironment. Ovarian surgery, especially when repeated or extensive, may also reduce the amount of residual functional tissue and impair local vascularisation. In these cases, primary ovarian insufficiency is often the result of a genuine anatomical or functional loss of the follicular reserve, and the likelihood of recovery depends on the extent of the residual damage.

The systemic pathophysiology is dominated by chronic hypoestrogenism. Reduced estradiol levels impair genitourinary trophism, disrupt menstrual regularity, reduce the quality of cervical mucus and the endometrium, promote hot flushes and vasomotor symptoms and interfere with sexual desire, arousal and comfort. In bone, oestrogen deficiency accelerates resorption by disrupting the balance of remodelling, resulting in progressive loss of mineral mass and greater susceptibility to osteopenia and osteoporosis. At the cardiovascular level, some of the favourable effects of oestrogens on endothelial function, lipid metabolism and body fat distribution are lost, while insomnia, irritability, anxiety, difficulty concentrating and impaired quality of life may occur at the neuropsychological and cognitive levels.

A central consideration is that primary ovarian insufficiency does not always correspond to complete ovarian inactivity. In some patients, intermittent ovarian function persists, with occasional ovulation and a reduced but genuine possibility of spontaneous conception. This pathophysiological feature explains why the condition should be described as insufficiency rather than simply ovarian failure. Its biological course may fluctuate, but the axis remains globally unable to ensure stable reproductive and hormonal function appropriate for age.

The clinical presentation of primary ovarian insufficiency is determined by three main dimensions: menstrual dysfunction, hypoestrogenism and reduced fertility. Presentation is highly heterogeneous. Some patients are assessed because of secondary amenorrhea after previously normal cycles, others report progressive oligomenorrhea, while others present with infertility as the first sign, particularly when residual ovarian activity remains intermittent and systemic symptoms are less apparent. In congenital or more severe forms, presentation may involve incomplete puberty or primary amenorrhea.

During the medical history, the first element to document accurately is menstrual history. The age at menarche, previous cycle regularity, any progressive reduction in menstrual frequency, episodes of prolonged amenorrhea and the presence of sporadic bleeding should be established. This temporal reconstruction has pathophysiological value because it helps distinguish progressive ovarian dysfunction from central, functional or iatrogenic conditions. Reproductive history should also be explored, including attempts to conceive, miscarriages, infertility, use of hormonal contraception and recent discontinuation that may have concealed or delayed recognition of the condition.

Symptoms of oestrogen deficiency include hot flushes, sweating, sleep disturbances, vaginal dryness, dyspareunia, reduced libido and mood instability. In many women, the condition is not immediately interpreted as endocrine because their young age makes the association with a menopausal hormonal profile less intuitive. Persistent fatigue, reduced concentration, irritability and a sense of impaired physical wellbeing may precede diagnosis and contribute to substantial delays, particularly when menstrual cycles are not completely absent but only irregular.

On physical examination, signs may be subtle in the early stages, although careful assessment may reveal important clues. Adolescents or young adults with early-onset forms may have incomplete pubertal development, limited breast development or syndromic features suggesting chromosomal causes. Patients with more prolonged hypoestrogenism may show hypotrophic genital mucosa, pain during intercourse, reduced lubrication and, over the long term, indirect signs of musculoskeletal impairment. General physical examination should also look for features of autoimmunity, thyroid abnormalities, phenotypic characteristics suggestive of Turner syndrome or mosaicism and evidence of previous oncological or surgical treatments.

The reproductive dimension carries considerable clinical weight. Infertility may be the main reason for consultation and is often associated with substantial psychological impact, uncertainty and reproductive grief. However, reduced fertility does not equate to the complete absence of spontaneous conception in non-surgical forms, because some residual ovarian activity may occasionally persist. This makes counselling more complex because both the severe reduction in reproductive potential and the possibility, although limited, of occasional ovulation must be communicated accurately.

Over time, if diagnosis is delayed and hypoestrogenism persists without treatment, broader consequences may emerge, including worsening quality of life, reduced bone mass, musculoskeletal pain, cardiovascular vulnerability and relational or sexual difficulties. Clinical manifestations should therefore not be reduced to amenorrhea alone, but interpreted as the expression of a chronic endocrine syndrome in a young woman, in which damage progressively accumulates unless interrupted by appropriate treatment.

Primary ovarian insufficiency should be suspected whenever a woman under the age of 40 presents with prolonged amenorrhea, oligomenorrhea or clearly irregular menstrual cycles, particularly when accompanied by symptoms of oestrogen deficiency. It is not necessary to wait for an overt clinical picture of early menopause before initiating investigations because many patients pass through a phase of fluctuating ovarian dysfunction in which menstrual activity has not completely ceased but is already biologically inadequate.

Suspicion should increase in the presence of hot flushes, sleep disturbances, vaginal dryness, reduced libido or unexplained infertility. In these circumstances, the association between cycle dysfunction and symptoms of oestrogen deficiency is highly suggestive. Even a young woman who reports apparently good general health but has persistent amenorrhea should not be reassured without further investigation because hypoestrogenism may already be adversely affecting bone and cardiovascular health before subjective symptoms become severe.

Particular attention should be paid to patients with a history of cancer, previous exposure to chemotherapy or radiotherapy, ovarian surgery, multiple autoimmune diseases or a family history of very early menopause. In these settings, the pre-test probability is substantially higher and endocrine assessment should not be delayed. Suspicion is similarly high in adolescents with absent pubertal progression or primary amenorrhea, particularly when short stature, syndromic features or other findings suggestive of a chromosomal abnormality are present.

It is essential to distinguish primary ovarian insufficiency promptly from functional or central forms of amenorrhea. A patient with marked underweight, extreme physical activity or severe psychological and metabolic stress may have hypothalamic amenorrhea, but ovarian damage should not be excluded automatically when the clinical pattern is not entirely consistent. Similarly, recent discontinuation of hormonal contraceptives should not lead to excessive delay when menstrual cycles fail to resume and symptoms of oestrogen deficiency develop.

Finally, clinical suspicion should rapidly lead to laboratory assessment because diagnostic delay prolongs exposure to hypoestrogenism and amplifies its consequences. In a young woman, loss of ovarian function is never a minor finding. It is an endocrine event with reproductive, skeletal, cardiovascular and psychological implications that requires early recognition and structured management.

The diagnosis of primary ovarian insufficiency requires an orderly process that confirms the endocrine disorder and identifies the underlying cause whenever possible. The first step is to recognise the combination of prolonged menstrual dysfunction and a biochemical pattern of hypergonadotropic hypogonadism. According to the 2024 ESHRE-ASRM-IMS international guideline, diagnosis is based on spontaneous amenorrhea or irregular menstrual cycles with biochemical confirmation, while avoiding premature conclusions based on a single isolated test or on non-diagnostic markers.

Diagnostic criteria for primary ovarian insufficiency

• Menstrual cycle disorder with amenorrhea or marked menstrual irregularity for at least 4 months.
• FSH > 25 IU/L in a compatible clinical context, with repeat measurement after 4 to 6 weeks if diagnostic uncertainty persists.
• A pattern consistent with reduced ovarian function, typically associated with low estradiol after exclusion of pregnancy and conditions that may conceal or alter the hormonal profile.
• Cautious interpretation following recent hormone therapy or hormonal contraception, which may conceal amenorrhea and modify FSH levels.

First-line investigations therefore include beta-hCG to exclude pregnancy and measurement of FSH, LH and estradiol, together with a basic assessment for possible endocrine differential diagnoses using TSH and prolactin. The purpose is to distinguish primary ovarian dysfunction promptly from hypothalamic-pituitary amenorrhea, hyperprolactinemia, pregnancy or other systemic conditions. FSH does not necessarily need to be measured on a specific day of the cycle when the patient is amenorrhoeic or markedly irregular. The essential requirement is clinical and biochemical consistency and, when necessary, confirmation several weeks later.

Once hypergonadotropic hypogonadism has been confirmed, the next step is aetiological investigation. In non-iatrogenic forms, the guideline recommends chromosomal analysis in all patients because karyotype abnormalities and mosaicism have diagnostic, prognostic and familial relevance. Testing for the FMR1 premutation is also recommended as a specific investigation because standard multigene panels do not reliably identify this abnormality. Where available and after genetic counselling, additional genetic testing may also be considered to identify other causative genes.

Autoimmune assessment should be targeted rather than indiscriminate. In cases of unknown cause, screening for 21-hydroxylase antibodies is recommended because the association with autoimmune adrenal insufficiency has greater potential clinical significance than other less specific autoantibodies. Thyroid function should always be assessed using TSH at diagnosis and reassessed over time according to clinical indications. By contrast, anti-ovarian antibodies are not sufficiently reliable to confirm or exclude an autoimmune form and should not become the central focus of diagnostic reasoning.

< b>Pelvic ultrasound contributes to structural assessment but is not diagnostic in itself. It may show small ovaries, a reduced antral follicle count or, in some patients, less marked abnormalities despite already impaired endocrine function. Its main value is to complement hormonal information, exclude concomitant pelvic disease and support reproductive stratification. In adolescents with suspected gonadal dysgenesis or abnormal pubertal development, imaging has even greater importance in the overall anatomical assessment.

The differential diagnosis should primarily include functional hypothalamic amenorrhea, hyperprolactinemia, pituitary disease, pregnancy, selected presentations of polycystic ovary syndrome, known iatrogenic ovarian insufficiency and medication-related amenorrhea caused by contraceptives or long-acting progestogens. The core of the diagnosis, however, remains demonstration that the disorder originates in the ovary and that negative feedback to the pituitary gland has been lost. Only at that point is the diagnostic assessment complete, allowing evaluation of risk, residual fertility and the long-term treatment plan.

The classification of primary ovarian insufficiency has practical clinical value because it links the biological mechanism to reproductive prognosis and follow-up decisions. The first distinction separates spontaneous from iatrogenic forms. Spontaneous forms include genetic, chromosomal, autoimmune and idiopathic causes. Iatrogenic forms result from chemotherapy, radiotherapy, ovarian surgery or other gonadotoxic treatments. This distinction is important because it changes the likelihood of functional recovery, family counselling and the relevance of preventive fertility preservation measures.

A second classification is aetiological. Chromosomal and syndromic forms tend to present earlier and may be associated with specific extragonadal phenotypes. Forms caused by the FMR1 premutation or other genetic variants may have a more variable expression and often require dedicated family counselling. Autoimmune forms frequently occur within the context of multiple endocrinopathies, while idiopathic forms still represent a substantial proportion of cases and are the category most likely to be reduced as future genetic discoveries clarify currently unclassified conditions.

From a clinical and functional perspective, it is useful to distinguish patients with complete absence of ovarian function from those with intermittent activity. This distinction does not alter the diagnostic definition but has important implications for counselling. A woman with fluctuating function may experience sporadic ovulation, spontaneous conception or occasional bleeding, while the probability of residual activity is virtually absent following anatomical or bilateral ovarian destruction. The hormonal regimen and need for contraception should also take this biological difference into account.

Another level of classification concerns the stage of life at which the disorder becomes apparent. Forms presenting with primary amenorrhea and absent or incomplete puberty have a different impact from forms that develop after years of normal menstrual cycles. In the first situation, the disorder also affects acquisition of peak bone mass, pubertal development and body identity. In the second, the initial impact is the disruption of an already established reproductive function, often with major consequences for family planning, sexuality and perception of health.

< b>Severity is not defined solely by FSH or estradiol levels, but by the combined degree of reproductive impairment, duration of hypoestrogenism, associated comorbidities and speed of recognition. A patient with prolonged hypoestrogenism, low bone density, vasomotor symptoms and dyspareunia has a greater clinical burden than a patient diagnosed early during the initial phase of menstrual irregularity. This dynamic view of severity is essential because it guides the intensity of monitoring, the need for multidisciplinary support and the urgency of treatment.

Treatment of primary ovarian insufficiency is based on three objectives: correcting hypoestrogenism, protecting long-term health and addressing reproductive issues realistically. The cornerstone is systemic hormone therapy, which is indicated in the absence of contraindications to reduce the risk of osteoporosis, support cardiovascular health, improve urogenital trophism and restore quality of life. Unlike therapy used after natural menopause, the rationale is not merely symptomatic, but involves replacing an endocrine function lost at a pathologically early age.

Treatment should generally continue until the average age of natural menopause. The approach most consistent with physiology is based on transdermal or oral estradiol, combined with a progestogen in women with a uterus to protect the endometrium. The international guideline indicates that optimisation of bone mineral density may require a daily dose equivalent to at least 2 mg of oral estradiol or 100 micrograms of transdermal estradiol, with the regimen tailored to the clinical presentation, tolerability and therapeutic goals. In young women with intermittent ovarian function who wish to retain the possibility of spontaneous conception, a sequential regimen is preferable to regimens that completely suppress cyclicity.

Treatment should not be delayed. Late initiation or poor adherence prolongs exposure to oestrogen deficiency and promotes bone loss, sexual dysfunction and deterioration in general wellbeing. In patients with marked genitourinary symptoms, targeted local interventions may be added to systemic therapy to improve dryness, pain during intercourse and mucosal vulnerability. Treatment should nevertheless be individualised, taking into account thromboembolic history, migraine, cardiovascular risk, personal preferences and the route of administration most compatible with good long-term adherence.

< b>Fertility requires clear counselling. In most women with primary ovarian insufficiency, there is no meaningful opportunity for fertility preservation at the time of diagnosis because the follicular pool has already been severely depleted. In patients at risk, however, fertility preservation should be discussed before gonadotoxic treatment. After a diagnosis of POI, oocyte donation remains the established reproductive strategy with the highest effectiveness, although it must be integrated into a pathway that considers aetiology, obstetric risk and the patient’s overall health. In certain situations, such as Turner syndrome or previous cardiotoxic oncological treatment, pregnancy may require particularly rigorous specialist assessment.

In addition to hormone therapy, treatment should include lifestyle measures and prevention of complications, including appropriate physical activity, adequate calcium and vitamin D intake when required, smoking cessation, maintenance of a healthy body weight and attention to cardiovascular risk factors. Psychological or psychosexual support may be crucial because the emotional burden of the diagnosis is often substantial and may impair treatment adherence, relationships and overall wellbeing.

Finally, treatment should be multidisciplinary when required by the aetiology. Turner syndrome, the FMR1 premutation, a history of cancer, polyautoimmunity or a substantial genetic concern significantly alters management. In these situations, the endocrinologist, reproductive gynaecologist, geneticist and, when necessary, cardiologist or other specialists should work in a coordinated manner because correction of the hormonal deficit represents only one component of comprehensive disease management.

Follow-up for primary ovarian insufficiency should be structured and continuous because the condition evolves over long periods and affects multiple target organs. The first objective of monitoring is to verify that hormone therapy adequately controls symptoms, provides bone protection and maintains overall wellbeing. This requires regular reassessment of vasomotor symptoms, sexual health, sleep quality, treatment adherence and tolerability of the different estradiol and progestogen regimens.

The skeletal system requires particular attention. Where available, the international guideline recommends DXA at diagnosis in all women with POI. If bone mineral density is normal and systemic therapy is adequate and consistently followed, the value of repeating DXA within the following five years is limited. When osteopenia, osteoporosis or additional risk factors are present, reassessment should be performed earlier and individualised, often every 1 to 3 years. Deterioration in bone mass requires review of treatment, nutrition, adherence and any additional factors contributing to bone loss.

< b>Endocrine and metabolic follow-up should also include surveillance for associated comorbidities. Thyroid function should be assessed at diagnosis and reassessed over time if symptoms develop or according to the schedule suggested by guidelines. In forms of unknown cause with positive adrenal autoantibodies or strong suspicion of autoimmunity, monitoring should also include adrenal function. Body weight, blood pressure, metabolic status and lifestyle should be assessed in parallel because early loss of ovarian function is associated with a less favourable cardiovascular risk profile than natural menopause.

< b>Reproductive follow-up is also essential. Patients should be informed that natural fertility is markedly reduced but not necessarily absent in non-surgical forms, which means contraception should be discussed when pregnancy is not desired. When pregnancy is desired, follow-up should include realistic counselling regarding the probability of spontaneous conception, the role of oocyte donation and the need to investigate the aetiology before planning pregnancy, particularly in the presence of genetic syndromes or previous cardiotoxic treatments.

The psychological and sexual dimension should not be marginalised. Anxiety, reproductive grief, reduced body confidence, relationship difficulties and persistent sexual dysfunction may continue even after laboratory correction of hypoestrogenism. High-quality follow-up should therefore provide clinical space for these issues, with psychological, psychosexual or specialist reproductive counselling when appropriate.

Finally, when a woman with POI reaches the age of natural menopause, the objectives of follow-up change. Management is no longer focused on replacing a function lost too early, but on reassessing the balance of risks and benefits of continuing hormone therapy as in the standard menopausal setting. This transition should not occur automatically, but through an individualised reassessment based on symptoms, skeletal and cardiovascular status and personal preferences.

The prognosis of primary ovarian insufficiency depends on the cause, age at onset, promptness of diagnosis and quality of replacement therapy and follow-up. From the perspective of survival, the condition is not an acute event in itself, but its prognostic importance is substantial because it results in additional years of exposure to hypoestrogenism. When recognition is delayed or treatment is absent, the cumulative risk of skeletal, cardiovascular, sexual and psychological complications increases significantly.

The most immediate complication in the natural history is subfertility or infertility, which is often the most clinically consequential aspect for the patient. In non-surgical forms, a small probability of spontaneous conception may persist because of intermittent ovarian activity, but this does not alter the fact that overall reproductive potential is markedly reduced. This makes the reproductive prognosis very different from that of other causes of amenorrhea and requires honest, early and specialist counselling.

< b>Skeletal complications arise directly from chronic oestrogen deficiency. Bone resorption exceeds formation, mineral density decreases and the risk of osteopenia, osteoporosis and fractures increases over time. Damage is greater when onset occurs earlier and the untreated period is longer. In patients who develop the condition during adolescence or young adulthood, the problem involves not only loss of previously acquired bone, but also failure to achieve an adequate peak bone mass.

< b>Cardiovascular complications are increasingly recognised. Premature loss of ovarian function is associated with a less favourable risk profile and an increased risk of cardiovascular disease, including coronary events, heart failure and stroke. The mechanism is multifactorial and includes loss of the vasoprotective effects of oestrogens, metabolic changes, altered endothelial function and possible interaction with traditional risk factors. Prognosis therefore depends not only on gynaecological management, but also on the quality of long-term cardiometabolic prevention.

< b>Urogenital, sexual and psychological complications are common and sometimes underestimated. Vaginal dryness, dyspareunia, reduced sexual desire, sleep disturbances, anxiety, depressed mood and impaired quality of life may persist for years if they are not actively addressed. This burden is compounded by the impact of receiving the diagnosis at a young age, which may generate isolation, a sense of loss and relational difficulties. In some women, the psychological burden is intensified by the need to make complex reproductive decisions within a short period of time.

Treatment itself may present challenges, but in a well-managed pathway these are generally manageable and do not alter the favourable balance of hormone replacement for most patients. The best prognosis is achieved when diagnosis is early, the aetiology is investigated correctly, treatment is initiated promptly and follow-up is genuinely multidimensional. Under these conditions, the burden of complications can be substantially reduced and the patient can regain a health trajectory much closer to that expected for her age.